Our mission is to become a fully-integrated international biopharmaceutical company, leveraging our deep experience in RNA therapeutics and novel delivery platform technologies to rapidly discover, develop and, if approved, commercialize a portfolio of transformative therapeutics and vaccines for patients suffering from a wide range of both rare and large market diseases.
Who We Are
We are the first and only clinical-stage RNA therapeutics biopharmaceutical company with a strong presence in both China and the U.S.* that is discovering and developing innovative drugs for indications with significant unmet medical needs and large market opportunities. We were founded in 2007 with the establishment of US Sirnaomics in Gaithersburg, Maryland. We are the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutic for our core product, STP705.
Our product pipeline is deep as it has broad therapeutic utility across rare and large market diseases including oncology, fibrosis-related diseases as well as antiviral and cardiometabolic diseases. We now have 5 ongoing clinical trials in phase I/II stage and another at least 14 other product candidates in IND enabling or advanced preclinical studies.
Our proprietary delivery platforms for administration of RNA-based therapeutics are the foundation of our product pipeline, including our polypeptide nanoparticle (PNP) delivery platform optimizable for local or systemic administration of RNAi therapeutics and targets beyond liver hepatocyte cells, our GalNAc-based delivery platforms for systemic administration and liver-targeting RNAi therapeutics, and our polypeptide lipid nanoparticle (PLNP) delivery platform useful for administration of mRNA vaccines and therapeutics.
